曲美他嗪治疗充血性心力衰竭的临床观察

目的探讨曲美他叹、对充血性心力衰竭患者的影响。方法30例缺血性心肌病和扩张性心肌病在常规治疗（洋地黄、利尿剂、血管紧张素转换酶抑制剂、硝酸酯类）基础上，口服曲美他嗪20mg，3次／d，6周后观察临床疗效。超声心动图测定治疗前后左室舒张末期内径（LVEDD）、左室射血分数（LVEF）及心功能的变化。结果治疗后LVEDD明显下降[（68．3±7．2）mmVS（53．2±5．4）mm，P〈0．01]，LVEF增加[（0．36±0．02）％VS（0．49±0．04）％，P〈0．05]，心功能改善1～2级。无发现与药物相关的不良反应。结论曲美他嗪能改善缺血性心肌病和扩张性心肌病的心功能。

Clinical observation of trimetazidine in the treatment of patients with congestive heart failure

Objective To explore the effects of trimetazidine on congestive heart failure in patients with ischemic cardiomyopathy and dilated cardiomyopathy. Methods Thirty cardiomyopathy patients （ 16 with ischemic cardiomyopathy and 14 with dilated cardiomyopathy）took trimetazidine 20rag after each of the three meals, besides routine therapy. Clinical effects were evaluated after 6 weeks of treatment. Left veutricular end diastolic diameter （LVEDD）,left ventricular ejection fraction （LVEF） of echocardiography and cardiac function （NYHA）were measured before and after the treatment of trimetazidine. Results After 6 weeks of therapy, LVEDD decreased significaently [ （68. 3 ±7.2）mm vs （53.2 ±5.4）mm,P 〈 0. 01 ], LVEF increased[ （0. 36± 0.02）% vs （0.49 ±0.04）% ,P 〈 0. 05] ,cardiac function（NYHA） improved 1 - 2 grade. There were no adverse reactions related to the drug. Conclusion Trimetazidine can improve the heart failure in patients with ischemic cardiomyopathy and dilated cardiomyopathy.